Fujii Takeshi, Nakamura Tetsuya, Iwamoto Aikichi
Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Japan.
J Infect Chemother. 2004 Feb;10(1):1-7. doi: 10.1007/s10156-003-0296-9.
The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment of SARS is largely anecdotal, and so far no treatment consensus has been reached. We summarize 14 clinical reports and attempt to assess the effectiveness of various treatment regimens. A combination treatment of steroids and ribavirin was widely used empirically from the outset of the epidemic. In general, the use of steroids for SARS seemed beneficial, but the optimal timing, dosage, and duration of treatment have not yet been determined. On the other hand, ribavirin administration apparently reduced neither the rate of intratracheal intubation nor that of mortality. Moreover, significant toxicity, such as hemolytic anemia, has been attributed to ribavirin. A few preliminary trials and in vitro data suggest the possibility of treating SARS with interferon. Other agents, including the HIV protease inhibitor glycyrrhizin and convalescent plasma, remain to be evaluated.
自2003年初以来,严重急性呼吸综合征(SARS)的爆发引起了全球的广泛关注并引发了恐慌。目前该疾病似乎已得到控制;然而,必须强调SARS可能会卷土重来。尽管已经报道了许多临床试验,但SARS的治疗很大程度上是基于个案经验,迄今为止尚未达成治疗共识。我们总结了14份临床报告,并试图评估各种治疗方案的有效性。从疫情开始,类固醇和利巴韦林的联合治疗就被经验性地广泛使用。总体而言,使用类固醇治疗SARS似乎有益,但治疗的最佳时机、剂量和持续时间尚未确定。另一方面,利巴韦林的使用显然既没有降低气管插管率,也没有降低死亡率。此外,利巴韦林还导致了诸如溶血性贫血等显著的毒性反应。一些初步试验和体外数据表明,使用干扰素治疗SARS具有可能性。其他药物,包括HIV蛋白酶抑制剂甘草甜素和康复期血浆,仍有待评估。